Compare LION & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | PLSE |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2025 | 2015 |
| Metric | LION | PLSE |
|---|---|---|
| Price | $10.90 | $51.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | $11.89 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.1M | 612.2K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,631,800,000.00 | N/A |
| Revenue This Year | N/A | $840.00 |
| Revenue Next Year | $22.98 | $287.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.88 | $12.56 |
| 52 Week High | $16.70 | $58.90 |
| Indicator | LION | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 54.39 |
| Support Level | $9.11 | $49.01 |
| Resistance Level | $11.02 | $58.90 |
| Average True Range (ATR) | 0.43 | 4.59 |
| MACD | 0.04 | -0.70 |
| Stochastic Oscillator | 32.03 | 35.18 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.